Clever Culture Developed AI Tools for Pathology Labs
The firm has invested over $50 million into automation technology designed to improve clinical diagnostic accuracy.
Updated on Oct. 4, 2026 in Biotech
Live Poll
Should healthcare systems prioritize AI-driven diagnostics to combat the rise of antibiotic-resistant superbugs?
Clever Culture Systems has deployed AI-powered diagnostic technology to assist pathology labs in managing culture plates. The system aims to enhance efficiency in clinical environments as global health organizations prioritize diagnostic stewardship.
Why it matters
Diagnostic stewardship initiatives seek to reduce unnecessary antibiotic use and address the critical evolution of drug-resistant bacteria. Automating lab processes helps identify infections faster, which is essential to combatting the rise of antimicrobial resistance.
The APAS Independence system utilizes AI to image and interpret culture plates, processing up to 200 plates per hour. Additionally, the company's Zone Reader module is currently available for research use only.
The players
Clever Culture Systems
This biotechnology company is listed on the ASX under the ticker CC5 and focuses on diagnostic laboratory automation.
World Health Organization
The United Nations agency is responsible for international public health and leads global initiatives against antimicrobial resistance.
Lumos Diagnostics
This company develops point-of-care diagnostic tests and recently received regulatory clearance for its respiratory assessment tools.
The details
The technology automates the visual analysis of agar culture plates to detect and sort potential infections. By streamlining these workflows, the company provides tools that support broader clinical efforts to identify bacterial threats more effectively.
Timeline
The WHO and Japan hosted a diagnostic stewardship meeting in September 2026.
Lumos Diagnostics secured a US CLIA waiver in March 2026.
Projected AMR-related deaths in the Western Pacific cover the period from 2020 to 2030.
The Tech Race
This development follows the pattern set by the WHO antimicrobial and clinical diagnostic stewardship initiative by providing technical infrastructure to support antibiotic optimization goals. These diagnostic tools compete to replace manual plate reading with automated systems, aiming to close the gap between infection identification and treatment.
Improved diagnostic speed can lead to faster identification of infections and more precise antibiotic prescriptions for patients. These efficiencies help reduce laboratory backlogs, potentially shortening the time individuals wait for medical test results.
The takeaway
Automated diagnostics are becoming essential in the fight against antimicrobial resistance as labs face rising sample volumes. Integrating AI into standard pathology workflows helps healthcare providers make faster, data-driven decisions regarding patient care.
Further reading
Learn more about the latest innovations in the Biotech sector.
Source note: This article includes information reported by Stockhead.
Live Poll
Should healthcare systems prioritize AI-driven diagnostics to combat the rise of antibiotic-resistant superbugs?
